



The choice of progestogen for the prevention of preterm birth in women with singleton pregnancy and prior preterm birth

Society for Maternal-Fetal Medicine (SMFM) Publications Committee

The practice of medicine continues to evolve, and individual circumstances will vary. This publication reflects information available at the time of its submission for publication and is neither designed nor intended to establish an exclusive standard of perinatal care. This publication is not expected to reflect the opinions of all members of the Society for Maternal-Fetal Medicine.

The Society for Maternal-Fetal Medicine (SMFM) continues to recommend that all women with a prior spontaneous preterm birth (PTB) of a singleton pregnancy be offered 17-alpha hydroxyprogesterone caproate (17OHP-C) therapy in a subsequent pregnancy with a singleton gestation.¹ Data from several sources suggest that despite these recommendations, there remains continued underutilization of 17OHP-C for eligible patients.²⁻⁵ The purpose of this statement is to reaffirm the choice of progestogen for women with a singleton gestation and a prior spontaneous PTB.

In 2003, Meis et al⁶ reported the results of a multicenter, double-masked, randomized controlled trial (RCT) involving 463 women with a singleton pregnancy and prior spontaneous PTB who received 17OHP-C or placebo. They found a 34% reduction in the incidence of recurrent PTB at <37 weeks of gestation with 17OHP-C treatment (from 54.9% to 36.3%).

The study was stopped early based on prespecified criteria because of findings at the second interim analysis (70% of the planned sample was analyzed). The RCT demonstrated significant reductions in both overall PTB and PTB at <32 and <35 weeks of gestation as well as significant reductions in infant complications (intraventricular hemorrhage, necrotizing enterocolitis, and a need for supplemental oxygen) in those receiving 17OHP-C.

In the same year, da Fonseca et al⁷ reported the findings of a double-masked RCT of 142 women at high risk for PTB (94% had a prior PTB) who received either 100 mg vaginal progesterone per day or placebo. This study reported a reduction in the incidence of PTB at <37 weeks of gestation (28.5% to 13.8%, $P = .03$) and <34 weeks of gestation (18.6% to 2.7%, $P = .002$).

Initial guidance from the American College of Obstetricians and Gynecologist and SMFM recommended

treatment with either 17OHP-C or vaginal progesterone for women with a prior spontaneous PTB to prevent recurrent PTB (2003, 2008).⁸ In addition, both prior to and after Food and Drug Administration approval of 17OHP-C because of issues with access (eg, cost, availability, insurance coverage), some experts argued for preferred use of vaginal progesterone, and many clinicians had no other options for their patients.⁹

In 2012, SMFM revised its recommendations by stating the following: "In singleton gestations with prior SPTB [spontaneous PTB] 20–36 6/7 weeks, 17P [17OHP-C] 250 mg IM [intramuscularly] weekly preferably starting at 16–20 weeks of gestation until 36 weeks of gestation is recommended."¹

The rationale for the change was based on findings from multiple RCTs. In 2007, O'Brien et al¹⁰ published the findings of a double-masked RCT involving 659 women with a singleton pregnancy and prior spontaneous PTB who received either 90 mg vaginal progesterone per day or matching placebo. This study reported no differences in PTB at <32 weeks of gestation (10.0% vs 11.3%; odds ratio [OR], 0.9; 95% confidence interval [CI], 0.52–1.56) or PTB at <37 weeks of gestation (41.7% vs 40.7%; OR, 1.08; 95% CI, 0.76–1.52) between those receiving vaginal progesterone vs placebo.

In 2011, Hassan et al¹¹ published the findings of their RCT comparing vaginal progesterone with placebo in women with a singleton pregnancy and sonographic short cervix (10–20 mm). In women without a history of a prior PTB (84% of the population), vaginal progesterone was associated with a lower rate of PTB at <33 weeks of gestation (7.6% vs 15.3%; risk ratio [RR], 0.50; 95% CI, 0.27–0.90, $P = .02$). However, in women with a history of a prior PTB between 20 and 35 weeks of gestation, there was not a statistically significant difference (15.8% vs 20.6%; RR, 0.77; 95% CI, 0.29–2.06, $P = .60$).

Similarly, in the RCT published in 2007 by Fonseca et al¹² comparing vaginal progesterone with placebo in women

with cervical length of <15 mm, those women with a history of a prior PTB had no statistically significant difference in the rate of a spontaneous PTB at <34 weeks of gestation. Moreover, data from the Does progesterone prophylaxis to prevent preterm labour improve outcome? (OPPTIMUM) study published in 2016 by Norman et al¹³ are consistent with these other trials and provide further support for the change in SMFM guidance.

The OPPTIMUM study was a large (n = 1228), multicenter, double-masked RCT comparing 200 mg of vaginal progesterone per day to placebo in women at high-risk for spontaneous PTB.¹³ In a subgroup of women with a history of a prior spontaneous PTB (n = 903), there were no significant differences in the rate of PTB at <34 weeks of gestation between those receiving vaginal progesterone and placebo (15.9% vs 18.8%).

A systematic review and meta-analysis published by Romero and colleagues in 2016 that included data from the OPPTIMUM study reported a decrease in PTB at <34 weeks of gestation or fetal death with vaginal progesterone vs placebo for women with a sonographically short cervix of <25 mm (pooled RR, 0.66; 95% CI, 0.52-0.83). However, the authors did not report outcomes for the subgroup of women with a history of a prior spontaneous PTB.

In summary, vaginal progesterone has not been adequately proven to decrease recurrent PTB in women with a history of a prior spontaneous PTB in multiple RCTs despite heterogeneity of patient populations, clinical criteria, and progesterone dosing. However, SMFM continues to affirm the use of vaginal progesterone to prevent PTB in women with a sonographically short cervix of ≤20 mm without a history of a prior spontaneous PTB.¹

Owen et al¹⁴ performed an RCT involving cervical cerclage in women with a prior spontaneous PTB at <34 weeks of gestation and noted that approximately 69% of those with serial cervical length screening had a cervical length that remained at >25 mm. A secondary analysis of this same RCT did not demonstrate any additional benefit of 17OHP-C in women who received a cerclage for cervical shortening.

In women with a prior spontaneous PTB who start 17OHP-C therapy and then develop cervical shortening, it remains unknown whether there is any benefit to change progesterone choice to vaginal progesterone (with or without cervical cerclage placement).¹⁵ Based on available data regarding the lack of benefit of vaginal progesterone in women with a history of a prior spontaneous PTB, we recommend the continuation of 17OHP-C therapy in women with a history of a prior spontaneous PTB throughout the pregnancy despite the development of cervical shortening (with or without cervical cerclage placement).

Few studies directly compare 17OHP-C and vaginal progesterone in women with a history of a prior spontaneous PTB.¹⁶⁻¹⁸ A recent meta-analysis reported outcomes for 3 trials that included a total of 680 women.¹⁹ The largest study to directly compare 17OHP-C and vaginal progesterone was conducted in Saudi Arabia and published in

2013 (this study accounts for 74% of subjects in the meta-analysis).¹⁸

In this Saudi Arabian study, 520 women with a history of 1 or more midtrimester PTBs or a history of cervical cerclage in a prior pregnancy were randomized to receive either 17OHP-C or vaginal progesterone; women receiving vaginal progesterone were less likely to deliver at <34 weeks of gestation than those receiving 17OHP-C (16.6% vs 25.7%; OR, 0.58; 95% CI, 0.37–0.89; *P* = .02) but not at <37 weeks of gestation (32.8% vs 35.3%). Enrollment in this study focused on a heterogeneous group of women with a cervical insufficiency phenotype (prior midtrimester preterm birth or cerclage), rather than the typical candidate for 17OHP-C in the United States. Given the significant differences in the study population, eligibility criteria, and study protocol, we believe this RCT is not generalizable to women with a prior spontaneous PTB in the United States.

Given the available data, this SMFM statement reaffirms its current recommendations: in women with a singleton gestation and a history of prior spontaneous PTB between 20 and 36 6/7 weeks of gestation, we recommend 17OHP-C at 250 mg intramuscularly weekly, starting at 16–20 weeks of gestation until 36 weeks of gestation or delivery, and vaginal progesterone should not be considered a substitute for 17OHP-C in these patients. ■

REFERENCES

1. Society for Maternal-Fetal Medicine Publications Committee, with assistance of Vincenzo Berghella. Progesterone and preterm birth prevention: translating clinical trials data into clinical practice. *Am J Obstet Gynecol* 2012;206:376-86.
2. Stringer EM, Vladutiu CJ, Manuck T, et al. 17 Hydroxyprogesterone caproate (17OHP-C) coverage among eligible women delivering at 2 North Carolina hospitals in 2012 and 2013: a retrospective cohort study. *Am J Obstet Gynecol* 2016;215:105.e1-12.
3. Rebarber A, Fox N, Klausner CK, Saltzman D, Roman AS. A national survey examining obstetrician perspectives on use of 17-alpha hydroxyprogesterone caproate post-US FDA approval. *Clin Drug Investig* 2013;33:571-7.
4. Yee LM, Liu LY, Sakowicz A, Bolden JR, Miller ES. Racial and ethnic disparities in use of 17-alpha hydroxyprogesterone caproate for prevention of preterm birth. *Am J Obstet Gynecol* 2016;214:374.e1-6.
5. Stringer EM, Vladutiu CJ, Batra P, Stringer JS, Menard MK. Operationalizing 17 alpha-hydroxyprogesterone caproate to prevent recurrent preterm birth: definitions, barriers, and next steps. *Obstet Gynecol* 2016;128:1397-402.
6. Meis PJ, Klebanoff M, Thom E, et al. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. *N Engl J Med* 2003;348:2379-85.
7. da Fonseca EB, Bittar RE, Carvalho MH, Zugaib M. Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo-controlled double-blind study. *Am J Obstet Gynecol* 2003;188:419-24.
8. Society for Maternal-Fetal Medicine Publications Committee. Use of progesterone to reduce preterm birth. ACOG Committee opinion number 419, October 2008 (replaces no. 291, November 2003). *Obstet Gynecol* 2008;112:963-5.
9. Silver RM, Cunningham FG. Deus ex Makena? *Obstet Gynecol* 2011;117:1263-5.

10. O'Brien JM, Adair CD, Lewis DF, et al. Progesterone vaginal gel for the reduction of recurrent preterm birth: primary results from a randomized, double-blind, placebo-controlled trial. *Ultrasound Obstet Gynecol* 2007;30:687-96.
11. Hassan SS, Romero R, Vidyadhari D, et al. PREGNANT Trial. Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix: a multicenter, randomized, double-blind, placebo-controlled trial. *Ultrasound Obstet Gynecol* 2011;38:18-31.
12. Fonseca EB, Celik E, Parra M, Singh M, Nicolaides KH, Fetal Medicine Foundation Second Trimester Screening Group. Progesterone and the risk of preterm birth among women with a short cervix. *N Engl J Med* 2007;357:462-9.
13. Norman JE, Marlow N, Messow CM, et al. OPPTIMUM Study Group. Vaginal progesterone prophylaxis for preterm birth (the OPPTIMUM study): a multicentre, randomised, double-blind trial. *Lancet* 2016;387:2106-16.
14. Owen J, Hankins G, Iams JD, et al. Multicenter randomized trial of cerclage for preterm birth prevention in high-risk women with shortened midtrimester cervical length. *Am J Obstet Gynecol* 2009;201:375.e1-8.
15. Berghella V, Figueroa D, Szychowski JM, et al. Vaginal Ultrasound Trial Consortium. 17-Alpha-hydroxyprogesterone caproate for the prevention of preterm birth in women with prior preterm birth and a short cervical length. *Am J Obstet Gynecol* 2010;202:351.e1-6.
16. Elimian A, Smith K, Williams M, Knudtson E, Goodman JR, Escobedo MB. A randomized controlled trial of intramuscular versus vaginal progesterone for the prevention of recurrent preterm birth. *Int J Gynaecol Obstet* 2016;134:169-72.
17. Bafghi AS, Bahrami E, Sekhvat L. Comparative study of vaginal versus intramuscular progesterone in the prevention of preterm delivery: a randomized clinical trial. *Electron Physician* 2015;7:1301-9.
18. Maher MA, Abdelaziz A, Ellaithy M, Bazeed MF. Prevention of preterm birth: a randomized trial of vaginal compared with intramuscular progesterone. *Acta Obstet Gynecol Scand* 2013;92:215-22.
19. Saccone G, Khalifeh A, Elimian A, et al. Vaginal progesterone compared to intramuscular 17-alpha-hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth in singleton gestations: a systematic review and meta-analysis of randomized controlled trials. *Ultrasound Obstet Gynecol*, in press.

All authors and committee members have filed a conflict of interest disclosure delineating personal, professional, and/or business interests that might be perceived as a real or potential conflict of interest in relation to this publication. Any conflicts have been resolved through a process approved by the Executive Board. The Society for Maternal-Fetal Medicine has neither solicited nor accepted any commercial involvement in the development of the content of this publication.

This document has undergone an internal peer review through a multilevel committee process within the Society for Maternal-Fetal Medicine (SMFM). This review involves critique and feedback from the SMFM Publications and Risk Management Committees and final approval by the SMFM Executive Committee. SMFM accepts sole responsibility for document content. SMFM publications do not undergo editorial and peer review by the American Journal of Obstetrics & Gynecology. The SMFM Publications Committee reviews publications every 18-24 months and issues updates as needed. Further details regarding SMFM Publications can be found at www.smfm.org/publications.

All questions or comments regarding the document should be referred to the SMFM Publications Committee at pubs@smfm.org.